Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Patent ExpiryFILSPARIPositive

AI Analysis

Summary

Travere Therapeutics received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering certain methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis.

Outcome Details

Notice of Allowance received for U.S. patent application

Importance:4/10

Sentiment:

0.60

PatentIntellectual PropertyFILSPARIFocal Segmental GlomerulosclerosisUSPTO

Related Companies

$TVTX

Read the original article

Published by yahoo_finance on September 23, 2026 11:00 AM

Read Original